Clinical trial
A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection
NCT04248426 is registered in ClinicalTrials.gov with Antios Therapeutics, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection
- Lead sponsor
- Antios Therapeutics, Inc
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 5, 2020
- Completion date
- May 18, 2021
- Enrollment
- 88 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.